Dirk Schadendorf

Dirk Schadendorf's AcademicInfluence.com Rankings

Dirk Schadendorf

Medical

#803

World Rank

#1053

Historical Rank

Dermatology

World Rank

#11

Historical Rank

medical Degrees

Dirk Schadendorf

Philosophy

#2994

World Rank

#4938

Historical Rank

Logic

#895

World Rank

#1461

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Dirk Schadendorf's Degrees

Doctorate Medicine University of Cologne
PhD Dermatology University of Cologne

Why Is Dirk Schadendorf Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dirk Schadendorf's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved survival with ipilimumab in patients with metastatic melanoma. (2010) (13093)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
Nivolumab in previously untreated melanoma without BRAF mutation. (2015) (4628)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) (3858)
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells (1998) (3018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) (2731)
A Landscape of Driver Mutations in Melanoma (2012) (2244)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) (2221)
Genomic Classification of Cutaneous Melanoma (2015) (2143)
Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) (2115)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (2015) (2032)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) (1781)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (2015) (1773)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Improved survival with MEK inhibition in BRAF-mutated melanoma. (2012) (1601)
TERT Promoter Mutations in Familial and Sporadic Melanoma (2013) (1539)
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (2015) (1348)
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012) (1230)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. (2000) (1187)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) (1137)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. (2010) (1068)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma (2017) (964)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (889)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. (2018) (874)
Melanoma (2018) (873)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. (2012) (819)
Highly Recurrent TERT Promoter Mutations in Human Melanoma (818)
PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma (2018) (807)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) (806)
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. (2014) (769)
Melanoma genome sequencing reveals frequent PREX2 mutations (2012) (695)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. (2013) (578)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) (577)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. (2016) (528)
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. (2006) (523)
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma (2014) (519)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. (2016) (467)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. (2006) (457)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) (449)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab (2016) (442)
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. (1993) (440)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network (2013) (411)
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. (2013) (381)
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. (2018) (377)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (376)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. (2018) (372)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (2017) (344)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (342)
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. (2009) (328)
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. (2013) (316)
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model (2011) (314)
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. (2017) (308)
Human mast cells produce IL-8. (1993) (307)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. (2022) (301)
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. (2012) (298)
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. (2017) (295)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab (2015) (285)
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism (2013) (279)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (276)
Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” (2013) (275)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. (2016) (270)
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. (2019) (257)
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (251)
Lack of clinical efficacy of imatinib in metastatic melanoma (2005) (246)
Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review (2018) (242)
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. (2012) (241)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging (2015) (240)
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. (2004) (231)
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial (2019) (224)
Metabolic heterogeneity confers differences in melanoma metastatic potential (2019) (222)
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. (2012) (219)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) (212)
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth (2012) (212)
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. (2020) (212)
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). (2011) (210)
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. (2014) (207)
Immunotherapy in melanoma: Recent advances and future directions. (2017) (206)
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. (2016) (200)
Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma (2015) (199)
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. (2013) (199)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells (2013) (198)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations (2018) (196)
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma (2015) (191)
Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma (2009) (189)
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study (2016) (188)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. (1997) (187)
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. (2012) (185)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. (2015) (183)
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. (2019) (183)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial (2019) (181)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma (2018) (176)
Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas (2013) (175)
Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B (2009) (174)
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study (1998) (174)
Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. (2012) (172)
Drug‐resistance in human melanoma (2001) (172)
Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. (2014) (171)
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. (2009) (171)
Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey (2011) (170)
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials (2015) (169)
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. (2005) (167)
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. (2010) (166)
Superior skin cancer classification by the combination of human and artificial intelligence. (2019) (165)
Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival (2002) (165)
Superior skin cancer classification by the combination of human and artificial intelligence. (2019) (165)
Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (162)
Melanocytes as "sensory" and regulatory cells in the epidermis. (1993) (160)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions (2017) (157)
Serological detection of cutaneous T-cell lymphoma-associated antigens. (2001) (157)
Deep neural networks are superior to dermatologists in melanoma image classification. (2019) (156)
The validity of circulating microRNAs in oncology: Five years of challenges and contradictions (2014) (156)
Increased expression of epidermal fatty acid binding protein, cofilin, and 14‐3‐3‐σ (stratifin) detected by two‐dimensional gel electrophoresis, mass spectrometry and microsequencing of drug‐resistant human adenocarcinoma of the pancreas (1999) (155)
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety (2014) (155)
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2021) (153)
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. (2013) (153)
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice (1999) (152)
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. (2014) (149)
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (2018) (148)
Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images. (2019) (148)
Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. (2005) (146)
Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. (2008) (145)
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. (2013) (145)
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control (2013) (145)
Genetic and morphologic features for melanoma classification (2010) (144)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (2020) (143)
The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling (2014) (142)
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. (2013) (137)
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma (2011) (136)
Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma (2000) (134)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. (2017) (132)
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. (2017) (131)
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma (2010) (131)
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2 (2002) (129)
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. (2002) (129)
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab (2016) (128)
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. (2007) (128)
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. (2017) (127)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial (2020) (126)
Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. (2005) (126)
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases (2013) (125)
B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis (2007) (124)
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (124)
Pathologist-level classification of histopathological melanoma images with deep neural networks. (2019) (124)
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials (2017) (124)
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. (2012) (123)
Vemurafenib Potently Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in BRAFV600E Melanoma Cells (2013) (123)
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells (2013) (123)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression (2014) (123)
Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. (2012) (120)
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. (2019) (119)
Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. (2003) (119)
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. (2019) (119)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) (119)
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. (2010) (119)
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial (2020) (116)
Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours (1993) (114)
The role of the proteasome activator PA28 in MHC class I antigen processing. (2002) (114)
Predictors of Sun Protection Behaviors and Severe Sunburn in an International Online Study (2010) (113)
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo (1996) (113)
Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up (2013) (112)
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. (2005) (112)
MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. (2017) (111)
Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) (2017) (111)
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two‐dimensional electrophoresis (2000) (110)
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (2020) (110)
Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation (1995) (109)
Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. (1995) (108)
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. (2009) (108)
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. (1998) (107)
PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. (2010) (107)
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial (2017) (107)
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. (2002) (106)
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. (2009) (105)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. (2021) (104)
LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations (2017) (103)
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma (2011) (102)
In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group (2006) (102)
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours (2013) (101)
Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events (2003) (100)
Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. (2015) (100)
DFNA5 (ICERE‐1) contributes to acquired etoposide resistance in melanoma cells (2001) (100)
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas (2014) (99)
Short German guidelines: Malignant melanoma (2008) (99)
An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma (2008) (98)
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade (2018) (97)
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. (1998) (95)
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. (2013) (95)
Somatic alterations in the melanoma genome: A high‐resolution array‐based comparative genomic hybridization study (2010) (94)
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. (2016) (93)
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. (2009) (93)
Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. (2008) (92)
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions* (2001) (91)
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene mgmt (2001) (91)
Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. (1998) (90)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (90)
Functional HLA‐DM on the surface of B cells and immature dendritic cells (2000) (90)
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. (2008) (89)
Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. (2012) (88)
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. (2018) (88)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). (2021) (88)
Small molecules and targeted therapies in distant metastatic disease (2009) (88)
Interferon‐γ down‐regulates NKG2D ligand expression and impairs the NKG2D‐mediated cytolysis of MHC class I‐deficient melanoma by natural killer cells (2009) (87)
Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (87)
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma (2008) (87)
Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (2016) (87)
Functional CCR9 expression is associated with small intestinal metastasis. (2004) (86)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial (2022) (85)
Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes (2016) (84)
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma (2010) (84)
Membrane transport proteins associated with drug resistance expressed in human melanoma. (1995) (83)
TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma (2013) (83)
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy (2008) (83)
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway (2015) (82)
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker (2013) (80)
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing (2020) (79)
Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. (2019) (79)
Melanoma in 2013: Melanoma—the run of success continues (2014) (78)
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. (2015) (78)
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. (2010) (78)
Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptides (2003) (78)
miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy (2014) (77)
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) (2003) (77)
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. (2007) (77)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (2018) (77)
Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma (2009) (76)
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion (2020) (76)
Genetic and clinico-pathologic analysis of metastatic uveal melanoma (2014) (75)
A Multimarker Prognostic Assay for Primary Cutaneous Melanoma (2009) (75)
Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response (2007) (74)
Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection: Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph Nodes. (2015) (74)
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. (2017) (74)
Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors (2019) (73)
MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. (2013) (72)
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. (2015) (72)
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6‐methylguanine‐DNA methyltransferase and N‐methylpurine‐DNA glycosylase in melanoma cells with acquired drug resistance (1999) (72)
Expression of interleukin‐8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma (1999) (71)
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. (2017) (70)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma (2020) (70)
Biomarkers in melanoma (2009) (70)
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma (2016) (70)
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. (2008) (69)
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
Genetic alterations and personalized medicine in melanoma: progress and future prospects. (2014) (69)
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma (2011) (69)
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. (2011) (68)
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs (2000) (68)
COVID-19-Related Fear and Health-Related Safety Behavior in Oncological Patients (2020) (68)
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. (2014) (68)
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance (2000) (67)
Melanocortin receptor 1 variants and melanoma risk: A study of 2 European populations (2009) (67)
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity (1994) (67)
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) (66)
Candidate genes for cross-resistance against DNA-damaging drugs. (2002) (66)
Enhanced expression of human ABC‐transporter tap is associated with cellular resistance to mitoxantrone (2001) (66)
Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. (2008) (66)
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. (2016) (65)
Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival (2011) (65)
Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. (2011) (65)
Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. (2002) (65)
Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles (2018) (65)
SF3B1 and BAP1 mutations in blue nevus-like melanoma (2017) (65)
Immunogenicity of Constitutively Active V599EBRaf (2004) (65)
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. (2003) (64)
Health-related quality of life results from the phase III CheckMate 067 study (2017) (64)
cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. (2003) (64)
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. (2020) (63)
Immunotherapy of distant metastatic disease (2009) (62)
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations (2017) (62)
Skin Melanoma Development in ret Transgenic Mice Despite the Depletion of CD25+Foxp3+ Regulatory T Cells in Lymphoid Organs1 (2009) (61)
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype (2004) (61)
Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study (2013) (61)
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq (2016) (61)
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study (2012) (61)
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. (2021) (60)
Behavioural conditioning as the mediator of placebo responses in the immune system (2011) (60)
Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. (2000) (60)
Tumor type M2 pyruvate kinase (TuM2‐PK) as a novel plasma tumor marker in melanoma (2005) (60)
Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-99mTc-nanocolloid hybrid tracer versus 99mTc-nanocolloid (2015) (60)
Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. (2003) (60)
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i (2020) (59)
Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. (1997) (59)
High frequencies of circulating melanoma‐reactive CD8+ T cells in patients with advanced melanoma (2000) (59)
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. (2018) (59)
Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients (2018) (58)
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial (2020) (57)
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. (2021) (56)
Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies (2007) (56)
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. (2012) (55)
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series (2019) (55)
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system (2016) (55)
S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version (2013) (55)
Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity (2000) (55)
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. (2020) (55)
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. (2011) (55)
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (2019) (55)
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (54)
Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. (2000) (54)
Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort (2015) (54)
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. (2006) (54)
Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors (2011) (53)
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. (2017) (53)
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. (2016) (53)
Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two‐dimensional electrophoresis, mass spectrometry and microsequencing (1999) (53)
Expression of CD44 variant isoforms in malignant melanoma. (1996) (53)
Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy (2006) (52)
NF1 mutations in conjunctival melanoma (2018) (52)
Melanoma and immunotherapy. (2009) (52)
Study of the development of chemoresistance in melanoma cell lines using proteome analysis (2003) (52)
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin (2002) (52)
Good shedder or bad shedder—the influence of skin diseases on forensic DNA analysis from epithelial abrasions (2011) (52)
Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies (2011) (52)
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? (2009) (52)
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe (2017) (52)
pHH3 Immunostaining Improves Interobserver Agreement of Mitotic Index in Thin Melanomas (2012) (51)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (51)
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine (2010) (51)
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours (2020) (51)
Identification of a new HLA‐A*0201‐restricted T‐cell epitope from the tyrosinase‐related protein 2 (TRP2) melanoma antigen (2000) (51)
Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles in cancer patients. (2008) (51)
β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. (2013) (51)
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. (2018) (51)
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. (2014) (50)
Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department (2010) (49)
Imatinib in melanoma: a selective treatment option based on KIT mutation status? (2007) (49)
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. (1996) (49)
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) (49)
Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. (2015) (49)
Detection of human papillomaviruses in paraffin-embedded condylomata acuminata--comparison of immunohistochemistry, in situ hybridization, and polymerase chain reaction. (1991) (49)
Study of Therapy Resistance in Cancer Cells with Functional Proteome Analysis (2002) (48)
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. (2016) (48)
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. (2019) (48)
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. (2019) (48)
Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI‐TOF mass spectrometry/bioinformatic approach (2007) (48)
Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) (2017) (47)
Differential Endothelial Adhesion Molecule Expression in Early and Late Whealing Reactions (1998) (47)
Expression of the c‐kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo (1995) (47)
Investigation of adhesion of modern wound dressings: a comparative analysis of 56 different wound dressings (2011) (47)
Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective (2020) (47)
Side effects of systemic oncological therapies in dermatology (2012) (47)
Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. (2006) (47)
Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. (2018) (47)
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. (2021) (47)
Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti‐angiogenic drug resistance? (2011) (47)
Enhanced P-selectin expression in chronic and dermographic urticaria. (1997) (47)
Melanoma risk factors, perceived threat and intentional tanning: an international online survey (2010) (46)
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. (2019) (46)
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance. (2018) (46)
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi (2017) (46)
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. (2014) (46)
Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma (2017) (46)
Tumor‐specific antigens in cutaneous T‐cell lymphoma: Expression and sero‐reactivity (2003) (45)
NAMPT signaling is critical for the proangiogenic activity of tumor‐associated neutrophils (2018) (45)
mRNA expression of tumor‐associated antigens in melanoma tissues and cell lines (2002) (44)
Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. (2016) (44)
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome (2010) (44)
Polidocanol foam sclerotherapy is a new and effective treatment for post‐operative lymphorrhea and lymphocele (2010) (44)
Increases in Adult Life Expectancy in Rural South Africa : Valuing the Scale-Up of HIV Treatment (44)
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). (2019) (44)
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study (2016) (44)
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (44)
Radio‐guided surgery: advantages of a new portable γ‐camera (Sentinella®) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignancies (2012) (43)
Cell-based vaccination against melanoma – background, preliminary results, and perspective (1999) (43)
Photoreceptor proteins as cancer‐retina antigens (2007) (43)
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. (2012) (43)
Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. (2016) (43)
The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma (2006) (42)
Cutaneous large B‐cell lymphoma of the leg masquerading  as a chronic venous ulcer (2002) (42)
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (42)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients (2004) (42)
Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. (1998) (42)
Endogenous μ‐opioid peptides modulate immune response towards malignant melanoma (2011) (42)
GBP-5 splicing variants: New guanylate-binding proteins with tumor-associated expression and antigenicity. (2004) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (2015) (41)
P‐glycoprotein expression in primary and metastatic malignant melanoma (1995) (41)
Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma (2017) (41)
Substance use and sexual risk behaviour among HIV‐positive men who have sex with men in specialized out‐patient clinics (2012) (40)
Linac-Based Radiosurgery of Cerebral Melanoma Metastases (2003) (40)
Primary Extracutaneous Malignant Melanoma: A Comprehensive Review with Emphasis on Treatment (2004) (40)
Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. (2010) (39)
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies (2019) (39)
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma (2022) (39)
mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma (2014) (39)
Risk loci for coronary artery calcification replicated at 9p21 and 6q24 in the Heinz Nixdorf Recall Study (2013) (38)
Glutathione and related enzymes in tumor progression and metastases of human melanoma. (1995) (38)
Childhood Psoriasis—An Analysis of German Health Insurance Data (2014) (38)
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. (2019) (38)
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. (2021) (38)
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk (2018) (38)
Dose-dependent severe cutaneous reactions to imatinib (2003) (38)
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma (2018) (38)
Drug Resistance in Human Melanoma: Mechanisms and Therapeutic Opportunities (2003) (38)
SEREX identification of new tumor antigens linked to melanoma‐associated retinopathy (2005) (38)
Cutaneous melanoma: A model to study cancer metastasis (2011) (38)
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. (2019) (37)
Photoacoustic imaging of real-time oxygen changes in chronic leg ulcers after topical application of a haemoglobin spray: a pilot study. (2016) (37)
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. (2017) (37)
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. (2017) (37)
Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. (1996) (37)
Serum manganese superoxide dismutase is a new tumour marker for malignant melanoma (1995) (37)
Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. (2016) (37)
Autologous dendritic cells for treatment of advanced cancer--an update. (2001) (37)
Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. (2006) (37)
Identification of tumor antigens and T-cell epitopes, and its clinical application (2004) (37)
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma (2021) (37)
SEREX identification of new tumour‐associated antigens in cutaneous T‐cell lymphoma (2004) (37)
Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma (2014) (36)
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis (2019) (36)
Recoverin as a cancer-retina antigen (2006) (36)
Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group (2007) (36)
Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. (2010) (35)
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. (2009) (35)
Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment (2002) (35)
Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations (2015) (35)
Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study (2017) (35)
Cancer‐retina antigens as potential paraneoplastic antigens in melanoma‐associated retinopathy (2009) (35)
Actinic keratoses treated with cold atmospheric plasma (2018) (35)
Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. (2000) (35)
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. (2020) (35)
Cognitive Factors Mediate Placebo Responses in Patients with House Dust Mite Allergy (2013) (34)
Verrucous cysts: histopathologic characterization and molecular detection of human papillomavirus‐specific DNA (1993) (34)
Indocyanine green fluorescence‐guided sentinel lymph node biopsy in dermato‐oncology (2012) (34)
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (2019) (34)
A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. (2005) (34)
Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme‐histochemical staining techniques (1994) (33)
Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. (2003) (33)
Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines (2007) (33)
Interleukin‐6 expression in the skin of patients with lupus erythematosus (1995) (33)
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. (2020) (33)
Melanoma brain metastases - Interdisciplinary management recommendations 2020. (2020) (33)
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. (2020) (33)
CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. (1998) (33)
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. (2019) (32)
Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanoma. (2010) (32)
Identification of selectively expressed genes and antigens in CTCL (2008) (32)
Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination. (2012) (32)
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. (2019) (32)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. (2014) (32)
Genese des chronischen Ulcus cruris bei 31 619 Patienten im Rahmen einer Expertenbefragung in Deutschland (2011) (32)
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. (2019) (31)
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. (2014) (31)
Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications (2000) (31)
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma. (2017) (31)
Expression of CD44 splice variants in human skin and epidermal tumours (1996) (31)
Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. (2014) (31)
Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-Line Treatment in Disseminated Melanoma (2004) (31)
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells (2009) (30)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (2020) (30)
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. (2022) (30)
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma (2020) (30)
Interleukin‐7. Biology and implications for dermatology (1996) (29)
Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms” (2013) (29)
The new face of nucleolin in human melanoma (2009) (29)
Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma (2003) (29)
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. (2021) (29)
Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis (2016) (29)
Kurzleitlinie – Malignes Melanom der Haut (2006) (29)
Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) (2012) (29)
The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma (2018) (29)
Humoral immune response against melanoma antigens induced by vaccination with cytokine gene‐modified autologous tumor cells (2004) (29)
Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing (2018) (29)
Quality assurance for care of melanoma patients based on guideline‐derived quality indicators and certification (2014) (28)
Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates (2004) (28)
A Skin Cancer Prevention Facial-Aging Mobile App for Secondary Schools in Brazil: Appearance-Focused Interventional Study (2018) (28)
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. (2020) (28)
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients (2018) (28)
Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines (2000) (28)
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. (2020) (28)
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. (2019) (28)
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis (2021) (28)
Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? (2015) (28)
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. (2015) (28)
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma. (2011) (28)
Vaccination of melanoma patients with peptide-pulsed dendritic cells: 047 (1997) (27)
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). (2019) (27)
Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib (2003) (27)
Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma (2016) (27)
[Brief guidelines: malignant melanoma of the skin]. (2006) (27)
Clinical and genetic analysis of melanomas arising in acral sites. (2019) (27)
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment (2021) (27)
Inherited variation in the PARP1 gene and survival from melanoma (2014) (26)
PLX4032: does it keep its promise for metastatic melanoma treatment? (2010) (26)
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients (2020) (26)
Reliability and cost‐effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II (2011) (26)
Surveillance and Follow-up Examinations in Cutaneous Melanoma (2003) (26)
Prognostic significance of spontaneous antibody responses against tumor‐associated antigens in malignant melanoma patients (2015) (26)
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. (2014) (26)
Amelanotic malignant melanoma presenting as malignant schwannoma (1993) (26)
Effects of Label Noise on Deep Learning-Based Skin Cancer Classification (2020) (26)
Human melanoma: drug resistance. (2003) (26)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2019) (26)
Frequent occurrence of high affinity T cells against MELOE‐1 makes this antigen an attractive target for melanoma immunotherapy (2010) (26)
Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient. (2012) (25)
The Efficiency of Human Cytomegalovirus pp65495–503 CD8+ T Cell Epitope Generation Is Determined by the Balanced Activities of Cytosolic and Endoplasmic Reticulum-Resident Peptidases (2012) (25)
Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. (2004) (25)
Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients (2002) (25)
Tumor-associated Antigens as Possible Targets for Immune Therapy in Head and Neck Cancer: Comparative mRNA Expression Analysis of RAGE and GAGE Genes (2002) (25)
Expression of GAGE family proteins in malignant melanoma. (2007) (25)
Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC). (2019) (25)
Update on the clinical use of kinase inhibitors in melanoma (2017) (25)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). (2012) (25)
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. (2011) (25)
Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition (2015) (25)
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. (2021) (24)
Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. (2009) (24)
Effects of various synthetic retinoids on proliferation and immunophenotype of human melanoma cells in vitro. (1995) (24)
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2007) (24)
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial (2011) (24)
Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? (2018) (24)
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. (2014) (24)
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain (2020) (24)
Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance. (2014) (24)
Integrated molecular drivers coordinate biological and clinical states in melanoma (2020) (24)
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. (2019) (24)
Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) (2021) (24)
EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up. (2011) (24)
Phenotypic characterization and prognostic impact of circulating γδ and αβ T‐cells in metastatic malignant melanoma (2016) (23)
Current advances and perspectives in the treatment of advanced melanoma (2012) (23)
New developments in biomarkers for melanoma (2013) (23)
Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review (2021) (23)
A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. (2006) (23)
High TERT promoter mutation frequency in non‐acral cutaneous metastatic melanoma (2016) (23)
Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study. (2000) (23)
S3‐Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0 (2017) (23)
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (23)
Is There a Standard for the Palliative Treatment of Melanoma? (2002) (23)
Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. (2017) (23)
Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling (2018) (23)
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma (2021) (23)
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. (2015) (23)
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (2018) (23)
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (2011) (23)
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020) (23)
HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model (2017) (23)
Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia. (2015) (22)
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis (2020) (22)
Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment (2018) (22)
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis (2016) (22)
Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA (2016) (22)
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes (2006) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy (2020) (22)
Photoaging Mobile Apps in School-Based Melanoma Prevention: Pilot Study (2017) (22)
Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study (2014) (21)
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group (2008) (21)
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. (2020) (21)
Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53 (2020) (21)
Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. (1994) (21)
Brain metastasis: opportunity for drug development? (2012) (21)
Targeting the H3K4 demethylase KDM5B reprograms the metabolome and phenotype of melanoma cells. (2019) (21)
IL-12 Production by Human Monocyte-Derived Dendritic Cells: Looking at the Single Cell (2005) (21)
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study (2013) (21)
Primary leiomyosarcoma of the skin. A histological and immunohistochemical analysis. (1993) (21)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM). (2012) (21)
A Medical Student-Delivered Smoking Prevention Program, Education Against Tobacco, for Secondary Schools in Germany: Randomized Controlled Trial (2017) (21)
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study. (2018) (21)
5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma (2019) (21)
Subacute cutaneous lupus erythematosus on the lines of Blaschko. (2006) (21)
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2016) (21)
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. (2015) (21)
Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel (2011) (20)
Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity. (2013) (20)
Lack of SF3B1 R625 mutations in cutaneous melanoma (2013) (20)
Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). (2017) (20)
Nine‐year follow‐up of a case of Grzybowski type multiple keratoacanthomas and failure to demonstrate human papillomavirus (2002) (20)
Combining BRAFV600E inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma (2015) (20)
MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma (2004) (19)
A rare primary sellar melanoma. Case report. (2004) (19)
Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2–Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice (2005) (19)
Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. (2010) (19)
Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma (2019) (19)
Advances and perspectives in immunotherapy of melanoma. (2012) (19)
Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized phase III study. (2004) (19)
Systemic therapies for melanoma brain metastases: which drug for whom and when? (2015) (19)
Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry. (2019) (19)
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. (2015) (19)
Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in Melanoma (2019) (19)
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma (2020) (19)
CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. (2015) (19)
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. (2020) (18)
Exposure to Melan-A/MART-126-35 tumor epitope specific CD8+T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS) (2016) (18)
Steroid‐induced Periorificial Dermatitis in Children—Clinical Features and Response to Azelaic Acid (2010) (18)
Antitumor activity of miR-1280 in melanoma by regulation of Src. (2015) (18)
Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells. (1994) (18)
Robustness of convolutional neural networks in recognition of pigmented skin lesions. (2021) (18)
Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide Libraries (2010) (18)
Prolongation of the QTc interval in HIV-infected individuals compared to the general population (2017) (18)
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplati (2002) (18)
Re: Association between endothelin receptor B nonsynonymous variants and melanoma risk. (2006) (18)
Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma (2008) (18)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) (18)
[Causes of leg ulcers. Analysis of the data from a dermatologic wound care center]. (2009) (18)
Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma (2022) (18)
Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts (2016) (18)
Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells (2000) (18)
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. (2016) (18)
Disseminated cutaneous Kaposi sarcoma and progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. (2007) (18)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. (2013) (17)
Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). (2017) (17)
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma (2018) (17)
Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. (2021) (17)
LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA (2014) (17)
Vitamin A metabolism in benign and malignant melanocytic skin cells: Importance of lecithin/retinol acyltransferase and RPE65 (2012) (17)
Effect of a Face-Aging Mobile App–Based Intervention on Skin Cancer Protection Behavior in Secondary Schools in Brazil (2020) (17)
Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic anti-tumor activity. (2019) (17)
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma (2017) (17)
Trametinib-Induced Remission of an MEK1-Mutated Langerhans Cell Histiocytosis. (2017) (17)
Blood T‐cell Vβ transcriptome in melanoma patients (2004) (17)
Complete remission of multiple satellite and in‐transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod (2006) (17)
Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients (2019) (17)
A benchmark for neural network robustness in skin cancer classification. (2021) (17)
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. (2018) (16)
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival (2016) (16)
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD. (2020) (16)
1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone (2017) (16)
LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA (2014) (16)
Mental Health Burden of German Cancer Patients before and after the Outbreak of COVID-19: Predictors of Mental Health Impairment (2021) (16)
Facial-Aging App Availability in Waiting Rooms as a Potential Opportunity for Skin Cancer Prevention (2018) (16)
Seroreactivity against MAGE‐A and LAGE‐1 proteins in melanoma patients (2003) (16)
[A new topically applied morphine gel for the pain treatment in patients with chronic leg ulcers: first results of a clinical investigation]. (2011) (16)
Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma (2003) (16)
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression (2017) (16)
Gene-based therapy of malignant melanoma. (2002) (16)
Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter. (1995) (16)
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
Fear of cancer progression in patients with stage IA malignant melanoma (2018) (15)
A skin cancer prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised controlled trial (2018) (15)
Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and Therapy (2012) (15)
Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not? (2013) (15)
The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. (2006) (15)
Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. (2010) (15)
T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma (2012) (15)
Patient-reported outcomes with nivolumab in advanced solid cancers. (2018) (15)
Mast cells in melanocytic tumours (2004) (15)
Industrial Forum · Industrieforum (2001) (15)
Human c-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. (1995) (15)
Integrin genes and susceptibility to human melanoma. (2012) (15)
A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic (2018) (14)
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. (2022) (14)
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. (2018) (14)
Unmet information needs of patients with melanoma in Germany (2019) (14)
Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. (2016) (14)
Peroxisome proliferator-activating receptors: a new way to treat melanoma? (2009) (14)
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab (2017) (14)
Information‐seeking and use of information resources among melanoma patients of German skin cancer centers (2018) (14)
Progression of malignant melanoma is associated with reduced 25‐hydroxyvitamin D serum levels (2008) (14)
Explainable artificial intelligence in skin cancer recognition: A systematic review. (2022) (14)
IRF4 rs12203592 functional variant and melanoma survival (2017) (14)
Detection of abacavir hypersensitivity by ELISpot method. (2012) (14)
Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP): A phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2006) (14)
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response (2013) (14)
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma. (2019) (14)
Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma? (2018) (14)
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine (2002) (14)
Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma Regression (2020) (14)
A smoking prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised trial (2017) (14)
Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing (2001) (14)
DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. (2011) (14)
Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT (2011) (14)
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. (2021) (14)
The phosphatidyl inositol 3‐kinase pathway is central to the pathogenesis of Kit‐activated melanoma (2011) (14)
Blood T-cell Vbeta transcriptome in melanoma patients. (2004) (13)
LBA7_PRBRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence (2017) (13)
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma (2016) (13)
Differentiation of monocyte-derived dendritic cells under the influence of platelets. (2008) (13)
Reliability and cost‐effectiveness of complete lymph node dissection under tumescent local anaesthesia vs. general anaesthesia: a retrospective analysis in patients with malignant melanoma AJCC stage III (2012) (13)
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047) (2022) (13)
Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (2018) (13)
CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. (2018) (13)
Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study (2021) (13)
Intracerebral metastases of malignant melanoma and their recurrences—A clinical analysis (2013) (13)
Melanoma patients respond to a new HLA‐A*01‐presented antigenic ligand derived from a multi‐epitope region of melanoma antigen TRP‐2 (2005) (13)
PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer (2018) (13)
Retinoic Acid receptor-gamma-selective retinoids exert antiproliferative effects on human-melanoma cell-growth in-vitro. (1994) (13)
Visible Light Modulates the Expression of Cancer-Retina Antigens (2008) (13)
Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma? (2016) (13)
The polymerase chain reaction. Method and applications in dermatopathology. (1993) (13)
Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV‐positive men who have sex with men (MSM) – approaches for medical prevention (2017) (13)
Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels. (2009) (13)
Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. (2010) (13)
Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al. (2015) (13)
Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB-IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study. (2018) (13)
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy (2016) (12)
Analysis of SDHD promoter mutations in various types of melanoma (2015) (12)
Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients (2003) (12)
In vivo selective expansion of a tumour‐specific cytotoxic T‐cell clone derived from peripheral blood of a melanoma patient after vaccination with gene‐modified autologous tumour cells (1999) (12)
Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
MITF is a critical regulator of the carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) in malignant melanoma (2015) (12)
Melanoma diagnosed in lesions previously treated by laser therapy (2017) (12)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
A novel heteromorphic human cell surface alloantigen, gp60, defined by a human monoclonal antibody. (1989) (12)
Treatment Algorithms in Stage IV Melanoma (2015) (12)
T CELL REPERTOIRE IN COMBINATION WITH T CELL DENSITY PREDICTS CLINICAL OUTCOMES IN PATIENTS WITH MERKEL CELL CARCINOMA. (2020) (12)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma : Comparison with Regulatory T Cells and NY-ESO-1-or MelanA – Speci fi c T Cells (2014) (12)
Characterization of gene regulatory elements for selective gene expression in human melanoma cells. (1995) (12)
Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. (1997) (12)
Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes: a retrospective analysis in 221 patients with malignant melanoma AJCC Stages I and II (2012) (12)
The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific (2006) (12)
A rare case of primary sellar melanoma (2009) (12)
Retarded low‐dose doxycycline for EGFR or MEK inhibitor–induced papulopustular rash (2014) (12)
In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons (1994) (11)
Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study. (2012) (11)
Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins (2007) (11)
NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. (2014) (11)
LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial (2021) (11)
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019) (11)
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors? (2019) (11)
Adjuvante Interferon-α-Therapie beim Melanom Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) (1998) (11)
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes (2020) (11)
Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs (2006) (11)
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. (2020) (11)
Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype. (1993) (11)
S3‐Leitlinie ,,Diagnostik, Therapie und Nachsorge des Melanoms” – Kurzfassung (2013) (11)
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma (2022) (11)
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma (2021) (11)
The predictive and prognostic significance of cell‐free DNA concentration in melanoma (2020) (11)
Genese des Ulcus cruris (2009) (11)
Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma. (2006) (11)
Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma (2018) (11)
Nodular scabies: hypersensitivity reaction or infection? (2011) (11)
The prognostic value of sentinel lymph nodes on distant metastasis-free survival in patients with high-risk squamous cell carcinoma. (2019) (10)
Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED) (2019) (10)
Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma (2013) (10)
Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. (2017) (10)
Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma (2021) (10)
Comparison of non-viral transfection methods in melanoma cell primary cultures. (2000) (10)
Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma. (2006) (10)
The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism. (2008) (10)
Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1 (2020) (10)
Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1 (2012) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. (2022) (10)
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma. (2018) (10)
Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term Therapy (2018) (10)
A Dermatologist's Ammunition in the War Against Smoking: A Photoaging App (2017) (10)
Combined treatment of stage IV melanoma patients with amifostine and fotemustine — a pilot study (1998) (10)
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. (2021) (10)
1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (10)
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) (2022) (10)
Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma (2016) (10)
Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) (2019) (10)
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG (2020) (9)
Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial (2019) (9)
Gene amplification by polymerase chain reaction in dermatology. (1991) (9)
1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS. (2014) (9)
SIRT1‐mediated deacetylation of FOXO3a transcription factor supports pro‐angiogenic activity of interferon‐deficient tumor‐associated neutrophils (2021) (9)
Persister state-directed transitioning and vulnerability in melanoma (2020) (9)
Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi (2019) (9)
Mixed effect modelling of proteomic mass spectrometry data by using Gaussian mixtures (2010) (9)
Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks (2015) (9)
Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial (2018) (9)
Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408). (2008) (9)
The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression (2016) (9)
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. (2014) (9)
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma (2022) (9)
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. (2018) (9)
Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature. (2016) (9)
1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone (2020) (9)
Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). (2014) (9)
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors (2021) (9)
BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419). (2014) (9)
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. (2021) (9)
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (9)
Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study (2020) (9)
Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification. (2018) (9)
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. (2020) (8)
Immunotherapy in non-melanoma skin cancer: updates and new perspectives (2019) (8)
Photopheresis in pediatric patients with low‐body weight using the UVAR® XTS™ system (2009) (8)
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection (2015) (8)
Giant pilomatricoma: a benign tumor in an uncommon presentation. (2009) (8)
Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR signaling. (2016) (8)
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (8)
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. (2021) (8)
Willingness to pay for a cure of low-risk melanoma patients in Germany (2018) (8)
Interferon‐γ downregulates epidermal growth factor receptors on human melanoma cells (1995) (8)
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis (2021) (8)
Is there a role for immune checkpoint blockade in metastatic uveal melanoma? (2015) (8)
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. (2020) (8)
Role of apaf-1 in melanoma drug resistance and apoptosis. (2005) (8)
Valvular manifestations of human immunodeficiency virus infection – results from the prospective, multicenter HIV-HEART study (2013) (8)
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities. (2021) (8)
Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells (2005) (8)
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial (2022) (7)
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. (2021) (7)
9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors (2009) (7)
CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma (2015) (7)
MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas. (2014) (7)
Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials (2021) (7)
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response (2020) (7)
Primary tumor versus metastasis: new experimental models for studies on cancer cell homing and metastasis in melanoma (2014) (7)
Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. (2006) (7)
1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) (2017) (7)
[Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy]. (1993) (7)
Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. (2017) (7)
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology (2020) (7)
Somatic gene therapy and its implications in melanoma treatment (1997) (7)
Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). (2018) (7)
Clinical Features and Classification (2013) (7)
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. (2021) (7)
Expectation‐induced placebo responses fail to accelerate wound healing in healthy volunteers: results from a prospective controlled experimental trial (2015) (7)
Gene-based immunotherapy of skin cancers. (2002) (7)
Interleukin 7 trials for melanoma treatment. (1996) (7)
Classical and variant Merkel cell carcinoma cell lines display different degrees of neuroendocrine differentiation and epithelial-mesenchymal transition. (2021) (7)
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. (2021) (7)
Tumor regression and sirolimus-based therapy in lung transplantation. (2013) (7)
Acute monoblastic leukemia with skin nodules in an adult. (1993) (7)
Human CD4+ T Lymphocytes Recognize a Vascular Endothelial Growth Factor Receptor-2–Derived Epitope in Association with HLA-DR (2008) (6)
Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma (1995) (6)
[External scientific evaluation of the first teledermatology app without direct patient contact in Germany (Online Dermatologist-AppDoc)]. (2020) (6)
New promises in the adjuvant, and palliative treatment of melanoma. (2007) (6)
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. (2014) (6)
DIG-labeled RNA in situ hybridization without coverslipping. (1995) (6)
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma (2018) (6)
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
Oncocardiology: new challenges, new opportunities (2020) (6)
Externe wissenschaftliche Evaluation der ersten Teledermatologie-App ohne direkten Patientenkontakt in Deutschland („Online Hautarzt – AppDoc“) (2020) (6)
Utilizing Artificial Neural Networks to Elucidate Serum Biomarker Patterns Which Discriminate Between Clinical Stages in Melanoma (2005) (6)
Systemic Treatment in Advanced Melanoma: Innovative Perspectives (2003) (6)
Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences (2019) (6)
Segregation of Effector Mechanisms in a Tumour‐Specific CD8+ T‐Cell Clone Correlates with CD30 Expression (2001) (6)
Oncogene Status of an Interdigitating Dendritic Cell Sarcoma: Recurrent Mutations in NF1, TP53, and ARID2 Shared With Melanoma. (2016) (6)
Dose-dependent toxicity of ipilimumab in metastatic melanoma. (2018) (6)
BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
Proteomics for biomarker discovery in malignant melanoma (2008) (6)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. (2019) (6)
STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-&agr; (2018) (6)
Multi-modal pooled Perturb-CITE-Seq screens in patient models define novel mechanisms of cancer immune evasion (2020) (6)
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians (2018) (6)
Immuntherapie beim malignen Melanom (2020) (6)
Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections—a cross-sectional, single-center study (2018) (6)
Preliminary study of micromechanical stress delivery for cell biology studies (2007) (6)
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management (2014) (6)
Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. (2016) (6)
Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters. (2019) (6)
The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. (2013) (6)
Adjuvante Interferon α− Therapie beim Melanom (1998) (6)
Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (6)
Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity (2021) (6)
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (5)
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study. (2022) (5)
Identification of HLA class I dependent immunogenic peptides from clonotypic TCRβ expressed in cutaneous T‐cell lymphoma (2006) (5)
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. (2021) (5)
Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study (2015) (5)
How melanoma is treated in real life. (2008) (5)
Expression of VLA-4 on primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels correlates with clinical outcome (2007) (5)
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study (2021) (5)
ER‐aminopeptidase 1 determines the processing and presentation of an immunotherapy‐relevant melanoma epitope (2019) (5)
ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry (2020) (5)
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients (2021) (5)
regulatory T cells impairs mouse melanoma growth (2012) (5)
[Psoriasis in children and adolescents. A nationwide physician survey on the healthcare situation in Germany]. (2012) (5)
Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8+ tumor-infiltrating lymphocytes. (2021) (5)
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma (2022) (5)
Sunday, 26 August 2012 (2012) (5)
Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. (2017) (5)
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. (2022) (5)
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy. (2021) (5)
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. (2022) (5)
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. (2022) (5)
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report (2020) (5)
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. (2022) (5)
Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation? (2004) (5)
The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. (2020) (5)
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). (2021) (5)
Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater‐blinded study (ACTICAP) (2020) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Release of stem cell factor during differentiation of human hacat keratinocytes (1994) (5)
B08CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL) (2015) (5)
Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS (2021) (5)
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (5)
Multicentre study on standardisation of melanoma cell culture – an initiative of the German Melanoma Research Network (2010) (5)
Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs). (2016) (5)
Complex Formation with Monomeric α-Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun’s Nuclear Translocation and Activity (2019) (5)
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology. (2021) (4)
Identification of a cross-reactive HLA-DRB1*0301-restricted CD4 T cell response directed against cholesterol-binding cytolysins from two different pathogens. (2006) (4)
Chemoresistance of malignant melanoma. Mechanisms and possible modulation (1994) (4)
Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (2018) (4)
Durchführung der Photopherese bei pädiatrischen Patienten mit niedrigem Körpergewicht mit dem UVAR® XTS™ System (2009) (4)
Myeloid-derived suppressor cells predict survival of advanced melanoma patients : comparison with regulatory T cells and NY-ESO-1-or MelanA-specific T cells (2013) (4)
Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report. (1998) (4)
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. (2017) (4)
Detection of Spontaneous CD 4 + T-Cell Responses inMelanoma Patients against a Tyrosinase-Related Protein-2 ^ Derived Epitope Identified in HLA-DRB 1 * 0301 TransgenicMice (2005) (4)
Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. (2017) (4)
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry (2021) (4)
Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient‐reported outcomes from the MIKIE study (2020) (4)
Hypomelanosis due to block of melanosomal maturation in amiodarone-induced hyperpigmentation. (2001) (4)
[Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology]. (2011) (4)
Perianale Ulzerationen durch Kaliumpermanganatbäder (2010) (4)
Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). (2012) (4)
Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma. (2013) (4)
Clinical application of noninvasive and nonradioactive determination of microscopic lymph node tumor status by multispectral optoacoustic imaging (2015) (4)
Rapid progression of a splenic aneurysm due to segmental arterial mediolysis: a rare cause of acute pancreatitis. (2013) (4)
Panel sequencing melanomas. (2015) (4)
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib (2021) (4)
Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. (2021) (4)
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) (4)
Segmentally arranged seborrhoeic keratoses with impending atypia and squamous cell carcinoma in an elderly woman (2015) (4)
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment (2022) (4)
Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes. (2015) (4)
The use of histamine in cancer immunotherapy. (2002) (4)
The genetic landscape of clinical resistance to RAF inhibition in melanoma. (2013) (4)
Intraventricular melanocytoma diagnosis confirmed by gene mutation profile (2018) (4)
Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation–Induced DNA Damage and Melanoma Susceptibility (2021) (4)
[Drug resistance of malignant melanoma. Mechanisms and possible modulation]. (1994) (4)
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis (2021) (4)
Postsurgical Treatment of Split Skin Graft Donor Sites in Dermatological Departments (2018) (4)
Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. (2006) (4)
A randomized trial of IFNα/IL-2 with or without CDDP in advanced melanoma: An EORTC melanoma cooperative group trial (1996) (4)
Evaluation of a Deep Learning Approach to Differentiate Bowen’s Disease and Seborrheic Keratosis (2022) (4)
Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
Vaccination with Dendritic Cells - A Specific Immunomodulatory Approach for the Treatment of Malignant Melanoma (1997) (3)
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. (2017) (3)
Reply to M. Perier-Muzet et al. (2014) (3)
The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. (2020) (3)
Merkelzellkarzinom (2019) (3)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma (2017) (3)
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. (2023) (3)
Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma (2018) (3)
PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. (2022) (3)
Palliativer Therapieansatz bei Fern-und Hirnmetastasen des malignen Melanoms mit Temozolomid und Hirnbestrahlung (2000) (3)
Brain metastases of metastatic malignant melanoma: Response to DTIC and interferon-gamma (1993) (3)
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172). (2016) (3)
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (2018) (3)
Web-based mindfulness and skills-based distress reduction for patients with cancer: study protocol of the multicentre, randomised, controlled confirmatory intervention trial Reduct (2022) (3)
Sensitivity of human melanoma cells in vitro to chemotherapy, interferons and combinations of both (1993) (3)
Tumorimmunologische Strategien in der Dermatoonkologie (2003) (3)
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival (2022) (3)
High-resolution three-dimensional imaging for precise staging in melanoma. (2021) (3)
STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients (2014) (3)
Garbe C, Hauschild A, Volkenandt M et al.Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17:393-399 (2008) (3)
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (3)
Adverse events of special interest in the phase 3 COLUMBUS study. (2018) (3)
Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up (2020) (3)
Systemic allergic contact dermatitis from intravenous piritramide (2010) (3)
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial (2017) (3)
Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cells. (2010) (3)
Psoriasis im Kindes- und Jugendalter (2012) (3)
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma (2021) (3)
23 A prospective randomised multi-centre trial for the treatment of primary high-risk melanoma using s.c. interleukin-2 and interferon-alpha (1995) (3)
Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL). (2015) (3)
Klippel-Trénaunay-Syndrom – eine seltene Ursache eines chronischen Ulcus cruris (2010) (3)
A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients (2009) (3)
Juvenile Psoriasis – Versorgungssituation und Lebensqualität in Deutschland (2013) (3)
Nebenwirkungen onkologischer Systemtherapien in der Dermatologie (2012) (3)
Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912). (2018) (3)
Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib. (2019) (3)
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. (2019) (3)
277 Human mast cell and basophil cell lines produce interleukin 8 and 6 (1991) (3)
Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy (2019) (2)
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG. (2022) (2)
Expression and functional activity of the IL-8 receptor by human mast cells (1994) (2)
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008 (2009) (2)
Immunotherapy of Melanoma: A New Era (2011) (2)
Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways (2019) (2)
NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts. (2017) (2)
Comparison of adherent lymphokine-activated killer (a-lak) cells generated by IL-2 and IL-7 - cellular modifications induced by IL-7. (1995) (2)
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma (2022) (2)
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib. (2014) (2)
1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047 (2021) (2)
Validating Automatic Concept-Based Explanations for AI-Based Digital Histopathology (2022) (2)
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). (2019) (2)
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. (2021) (2)
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (2)
Detergent fractionation with subsequent subtractive suppression hybridization as a tool for identifying genes coding for plasma membrane proteins (2009) (2)
Development Process of Quality Indicators for the S3-Guideline Melanoma (2013) (2)
Conference on cancer vaccines (2000) (2)
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity (2022) (2)
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study (2021) (2)
Evaluation of the Melanoma Tumor Burden Score (MTBS) in a real-world setting. (2017) (2)
Comparison of mutation profiles in primary melanomas and corresponding nodal naevi using next‐generation sequencing (2021) (2)
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial. (2021) (2)
Kurzleitlinie: Malignes Melanom der Haut (2006) (2)
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma (2022) (2)
Cytokines and Cytokine Gene Transfer in Cancer Treatment (1997) (2)
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) (2022) (2)
Melanocortin receptor 1 variants and melanoma risk – a study on two European populations (2008) (2)
Angioplasmacellular Hyperplasia—A New Histopathologic Clue for Anogenital Herpes Simplex Recidivans in Immunocompromised Patients? (2014) (2)
Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. (2020) (2)
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy (2022) (2)
Introduction to Cutaneous Melanoma (2013) (2)
Handbook of cutaneous melanoma (2013) (2)
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (2018) (2)
Differential promoter activity in benign and malignant human cells of skin origin * (1995) (2)
1224PDAnalysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002 (2017) (2)
High-resolution 3-D imaging for precise staging in malignant melanoma (2020) (2)
[Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group]. (1998) (2)
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) (2)
1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma (2020) (2)
[Acute juvenile pityriasis rubra pilaris in a 2-year-old child]. (2004) (2)
Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials (2019) (2)
Treatment in metastatic melanoma-time to re-think. (2019) (2)
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (2)
EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition. (2022) (2)
Treatment in metastatic melanoma-time to re-think. (2019) (2)
Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation (2021) (2)
Cell Receptor NKG 2 D KillerExpression of ULBP 2 , a Stress-Induced Ligand of the Natural Tumor Suppressive MicroRNAs miR-34 a / c Control Cancer Cell (2012) (2)
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. (2022) (2)
[90-year-old male with a hyperkeratotic lichenoid skin eruption]. (2005) (2)
[Information services for melanoma patients and awareness among those affected]. (2018) (2)
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. (2022) (2)
Most Cited Authors... (2008) (2)
The Janus-faced role of KDM5B heterogeneity in melanoma: differentiation as a situational driver of both growth arrest and drug-resistance (2020) (2)
1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma (2021) (2)
Salivary cortisol levels and anxiety in melanoma patients undergoing sentinel lymph node excision under local anesthesia versus general anesthesia: a prospective study (2020) (2)
The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity (2022) (2)
Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. (2022) (2)
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. (2017) (2)
787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial (2022) (2)
Human Mast Cells IL-8 Receptor Type CXCR 1 and CXCR 2 on Expression and Functional Activity of the (1998) (2)
Placebo responses in patients with house dust mite allergy (2013) (2)
B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV: Results from the HIV-HEART study. (2019) (2)
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). (2018) (2)
Sebaceous tumours: more than skin deep (2017) (2)
Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) (2019) (2)
Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. (2011) (2)
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) (2020) (2)
Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients (2005) (2)
Determination of granulocyte/macrophage-colony-stimulating factor secretion by human melanoma cells and its effects on human melanoma cell proliferation (2005) (2)
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren (2011) (2)
Update der S3-Leitlinie zum malignen Melanom (2017) (2)
Medikamentöse Systemtherapie des Melanoms (2014) (2)
Prognose des primären und metastasierten malignen Melanoms : Abschliessende Auswertung des geschlossenen Patientenkollektivs an der Hautklinik des Virchow Klinikums, Berlin, von 1981 bis 1995 (1996) (2)
Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms (2012) (2)
Informationssuche und Nutzung von Informationsquellen durch Melanompatienten deutscher Hautkrebszentren (2018) (2)
Leitlinienbasierte Qualitätsindikatoren und Zertifizierung als Grundlage für die Qualitätssicherung der Versorgung von Patienten mit Melanom (2014) (2)
Ultraschall in der Therapie chronischer Wunden (2009) (2)
Interleukin-7 in der Dermatologie Molekulare, immunologische und präklinische Aspekte (1995) (2)
Abstract 1977: The protein phosphatase 2 subunit PR48 is a novel melanoma tumor suppressor gene. (2013) (1)
Tumor necrosis factor alpha blockade prevents immune checkpoint inhibitor therapy-related cardiotoxicity (2020) (1)
Laser-Assisted Delivery Of Cold Atmospheric Plasma In Unresectable Cutaneous Metastasis In Melanoma Patients (2018) (1)
767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY (2008) (1)
Predictors of quality of life in melanoma patients 4 years after diagnosis: Results of a nationwide cohort study in Germany (2018) (1)
Informations‐ und Hilfsangebote für Melanompatienten: Präferenzielle Unterschiede zwischen Patienten und Ärzten (2019) (1)
Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction (2020) (1)
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (1)
Best supportive care in combination with polychemotherapy versus best supportive care alone as second-line therapy in stage IV metastatic melanoma (DeCOG MM-PAL 8) (2007) (1)
Tumorspezifische Therapieansätze in der Onkologie (2001) (1)
Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy (2015) (1)
Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. (2022) (1)
Medikamentöse Therapie des metastasierten Melanoms im Rahmen prospektiv-randomisierter Studien (2004) (1)
1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL. (2014) (1)
Pilomatrixkarzinom mit lymphogener Metastasierung - ein Fallbericht (2004) (1)
Cancer Patients’ Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy: A Clinical Waitlist Control Study (2022) (1)
Immune checkpoint blockade for organ-transplant recipients with cancer: A review. (2022) (1)
EUMelaReg: A European platform for outcome research on real world treatment data of patients with advanced melanoma. (2018) (1)
Diagnosis and Follow-up of Melanoma - what will change with the new S3 Guideline? (2013) (1)
819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial (2022) (1)
Obesity is associated with altered tumor metabolism in metastatic melanoma. (2022) (1)
Hat die Vakzination von Tumorpatienten eine Zukunft in der klinischen Onkologie? (2002) (1)
Framingham risk score and cardiovascular risk profiles in HIV+ patients and HIV- controls differ by sex (2013) (1)
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG (2022) (1)
Prospective comparative study of two rehabilitation schemes in 2354 patients with malignant melanoma (2011) (1)
Rational Development of Peptide Vaccination in Clinical Oncology. Concerning Jäger E, et al.: Peptide vaccination in clinical oncology. Onkologie 2000;23:410–415. (2001) (1)
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus‐19 vaccine‐associated lymphadenopathy (2023) (1)
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]. (2018) (1)
Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data. (2019) (1)
Differential in fl uence of vemurafenib and dabrafenib on patients ’ lymphocytes despite similar clinical ef fi cacy in melanoma (2014) (1)
Sexualverhalten, STIs und HIV‐Übertragungsrisiken bei HIV‐positiven MSM – Ansätze für die ärztliche Präventionsarbeit (2017) (1)
2416PD1-blocking immune checkpoint inhibitor therapy for malignant melanoma induces left ventricular dysfunction (2019) (1)
Elimination of Dendritic Cells in Cancer (2009) (1)
Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
Immuntherapie des Melanoms (2012) (1)
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors (2022) (1)
Merkel-Zell-Karzinom (2021) (1)
Alternative Strategien in der Therapie des malignen Melanoms (1997) (1)
[Perianal ulcerations caused by potassium permanganate bath]. (2010) (1)
Metastatic recurrence of 17‐year relapse‐free melanoma during anti‐TNFa therapy (2017) (1)
Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C). (2013) (1)
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity (2022) (1)
Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). (2019) (1)
Abstract 4714: Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. (2013) (1)
FC10 Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial (2010) (1)
Chemotherapie des fortgeschrittenen malignen Melanoms - Ein Überblick anhand der Ergebnisse randomisierter kontrollierter klinischer Studien - (2002) (1)
Entscheidungsfindung für die klinische Praxis: Aktuelle Konzepte und Behandlungsalgorithmen mit Immun-Checkpoint-Inhibitoren beim Melanom (2016) (1)
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma (2016) (1)
miR-101 is dysregulated in malignant melanoma and targets MITF (2010) (1)
Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients. (2013) (1)
‘PEG meets Liposome’ – zwei Technologien führen zu einer Substanz mit neuem Profil (2001) (1)
25 Update of EORTC melanoma trials. Final results of the EORTC melanoma group trials: EORTC 18951 in stage IV and EORTC 18952 in stage IIB–III (2004) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial. (2014) (1)
871P Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial (2022) (1)
Biology of Human Tumors Circulating CD 4 þ T Cells That Produce IL 4 or IL 17 When Stimulated by MelanA but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma (2014) (1)
Chemoresistance in Cancer Cells (2004) (1)
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (1)
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma (2022) (1)
PHASE I TRIAL OF ADJUVANT VACCINATION WITH TYROSINASE PEPTIDES AND GM-CSF IN MELANOMA (1999) (1)
90jähriger Patient mit hyperkeratotisch‐lichenoiden Hautveränderungen (2005) (1)
Reply to E. Hindié and K.R. Hess. (2019) (1)
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype (2022) (1)
PO-332 Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E-inhibition in melanoma (2018) (1)
Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. (2022) (1)
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial. (2018) (1)
Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma (2010) (1)
NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients With Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed After Immunotherapy (2014) (1)
Diagnostische Anstrengungen in der Melanomnachsorge : welche werden belohnt ? (1999) (1)
Genetc and morphologic features for melanoma classification: implications for clinical trials (2010) (1)
Neurofibromatose Typ 1 - Klinik und Genetik (Synonym: Morbus von Recklinghausen) (2004) (1)
P35 Status quo of the S3 guideline ‘Diagnosis, treatment and follow-up of melanoma’ in Germany (2010) (1)
UV-Schutz-Bündnis in Deutschland – Zweck und Ziele (2022) (1)
Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches (2008) (1)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (1)
The price of tumor control (2013) (1)
Advancements in melanoma cancer metastasis models (2022) (1)
1192PCytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis (2017) (1)
One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website-A Mixed-methods Approach. (2022) (1)
Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis. (2021) (1)
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. (2018) (1)
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy (2021) (1)
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition (2022) (1)
Fatal swelling of the groin – Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma (2020) (1)
Association between the B-RAF/N-RAS mutations, the CDKN2A alterations and the MC1R variants in melanoma (2006) (1)
Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). (2019) (1)
Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma (2018) (1)
1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results (2021) (1)
UV-Schutz-Bündnis in Deutschland – Zeitstrahl der inhaltlichen Entwicklung (2022) (1)
Immuntherapie des Melanoms (2012) (1)
Activation of p 38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to BecomeTolerogenic in Ret Transgenic Mice Spontaneously DevelopingMelanoma (2009) (1)
[Gene therapy in malignant melanoma. Interview with D. Schadendorf]. (1996) (1)
Informationsangebote für Melanompatienten und ihre Bekanntheit unter Betroffenen (2018) (1)
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (2022) (1)
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence. (2022) (1)
[Early detection for prevention of malignant melanoma in Berlin]. (1992) (1)
Reply to the letter to the editor: 'Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images'. (2020) (1)
Effektive Lymphknotendissektion bei primärem malignen Melanom Hautarzt (1996) 47:29–34 (1996) (1)
Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM) (2019) (1)
Active remodeling of capillary endothelium via cancer cell-derived MMP9 promotes metastatic brain colonization. (2023) (1)
Adjuvant pegylated interferon α-2b therapy for melanoma. (2010) (1)
Impact of a functional polymorphism in the IL12B promoter region on survival in patients with malignant melanoma. (2016) (1)
Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems (2021) (1)
Enforced polarization of melanoma cells towards a JARID1B-high phenotype exhausts tumour fitness (2017) (1)
Pegylated liposomal doxorubicin plus paclitaxel as an individualized chemosensitivity-directed treatment in advanced metastatic melanoma (2007) (0)
Authors' reply (2000) (0)
Abstract 3514: A genetic-metabolic circuit of liver-specific metastatic organotropism (2023) (0)
Cancer Therapy : Clinical Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermato fi brosarcoma Protuberans : AMulticenter Phase II DeCOG Trial with Long-term Follow-up (2014) (0)
Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population. (2023) (0)
Checkpointinhibitoren@@@Checkpoint inhibitors (2017) (0)
Neuropilin-1 mediates infiltration of regulatory T cells into tumors favoring immune escape (P2063) (2013) (0)
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD. (2022) (0)
Neo-adjuvant Therapy of Dermatofibrosarcoma protuberans with Imatinib: A multicenter Phase II Study of the ADO (2013) (0)
Interferon T downregulates EGF-R expression on human melanoma cells—determination of the relevance of EGF and EGF-R on proliferation of human melanoma cells (1993) (0)
Identifizierung von spezifischen Plasmamembranproteinen des kutanen T-Zell Lymphoms (2004) (0)
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases. (2021) (0)
Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2023) (0)
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2021) (0)
4. Interdisziplinärer Kongress „Quality of Cancer Care“ (QoCC 2019) (2019) (0)
Nucleic acid, the protein of the CTAGE family encodes a whose use and preparation (2000) (0)
Chemotherapy of metastatic malignant melanoma directed by in vitro sensitivity testing: 164 (1993) (0)
Fear of progression in patients with low-risk malignant melanoma. (2017) (0)
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (0)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (0)
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. (2022) (0)
Revised guidelines for authors of gene mapping reports (2000) (0)
Prognostic factors in the surgical treatment of melanoma lung metastasis: a high-volume single center experience (2017) (0)
Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3 (2023) (0)
Reply to E. Hindié. (2021) (0)
Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells (2010) (0)
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma (2023) (0)
Melanoma and Immunother apy (2009) (0)
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (0)
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma (2023) (0)
Corrigendum to Letter to the Editor: Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT (2011) (0)
Metastatic pigmented epithelioid melanocytoma in a 7‐year‐old female (2021) (0)
Vorwort (2013) (0)
Vorwort (2012) (0)
817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047 (2022) (0)
Update (1972) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI). (2015) (0)
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. (2012) (0)
Activity of viral promotors in cultered human skin cells (1993) (0)
Metabolic heterogeneity confers differences in melanoma metastatic potential (2019) (0)
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates (2022) (0)
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants (2022) (0)
Band 24, Heft 2, April 2001 (2001) (0)
Vorwort (2001) (0)
Dr. Dirk Schadendorf (2017) (0)
The European Searchable Tumour Cell and Databank, ESTDAB, as a tool for research in cancer immunology (2004) (0)
Nodöse Scabies: Hypersensitivitätsreaktion oder Infektion? (2011) (0)
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study. (2021) (0)
Genetic and Dendritic Cell Vaccination as a Novel Therapy for Melanoma (2001) (0)
An essential interdisciplinary partnership of Nuclear Medicine and Dermato-Oncology: Advantages of preoperative SPECT/CT detecting sentinel lymph nodes in malignant melanoma (2011) (0)
Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells (2020) (0)
Optimale Systemtherapie beim kutanen Melanom (2017) (0)
Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. (2015) (0)
Multicenter study on prognostic factors in 692 patients with brain metastases of malignant melanoma. (2009) (0)
Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) (0)
Treatment of Distant and Irresectable Metastatic Disease (2013) (0)
Gene Therapy: A New Perspective for the Treatment of Malignant Melanoma (1997) (0)
1075P Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma (2021) (0)
Photoreceptor proteins as cancer-retina antigens in melanoma (2006) (0)
1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma (2021) (0)
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis. (2023) (0)
Diagnosis, Staging, and Follow-up (2013) (0)
136-78: PROLONGATION OF THE QTc INTERVAL IN HIV INFECTED INDIVIDUALS COMPARED TO THE GENERAL POPULATION (2016) (0)
1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO (2020) (0)
786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma (2022) (0)
EORTC Melanoma Group achievements (2012) (0)
[State-of-the-art pharmacotherapy of malignant melanoma]. (2011) (0)
Apoptosis in Melanoma Approaches to Therapy (0)
Subject Index Vol. 26, 2003 (2003) (0)
Database for queries of melanoma cohorts with molecular and clinical data (2022) (0)
Subject Index Vol. 87, 1999 (2000) (0)
B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma. (2023) (0)
PO-493 ctDNA profiles of metastatic melanoma patients under therapy (2018) (0)
Keyhole Limpet Hemocyanin (KLH)-pulsed dendritic cells induce longterm Th1-type immune response in patients with metastatic melanoma (1998) (0)
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. (2023) (0)
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma (2022) (0)
7503-114079-1-Sp (2016) (0)
Response. (2015) (0)
P44. Mouse models of spontaneous melanoma as a tool for development of new immunotherapies of human melanoma (2006) (0)
Reply to M. Horiguchi et al. (2018) (0)
3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective (2015) (0)
Band 25, Supplement 1, März 2002 (2002) (0)
Immunization strategies in advanced melanoma (1999) (0)
Epitheloides malignes Schwannom (EMS) der Haut : Differentialdiagnose und Fallbericht (1998) (0)
Consultant Oral Session Abstracts (2018) (0)
1226PDFive-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma (2017) (0)
Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial (2018) (0)
Acanthosis nigricans (2010) (0)
Title Page / Contents / Imprint (2014) (0)
PO-399 Tumour CDKN2A loss predisposes to immunotherapy resistance (2018) (0)
Melanoma Group achievements (2012) (0)
Association of single-nucleotide polymorphisms in DNA repair genes with progression and survival of primary cutaneous melanoma patients (2008) (0)
Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients (2018) (0)
784O Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial (2022) (0)
Apoptosis in BRAFV600E Melanoma Cells Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated ` (2013) (0)
Melanoma vaccines. (2000) (0)
Eine Übersicht über Therapiefortschritte in den letzten 50 Jahren beim Metastasierten Melanom (2016) (0)
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib. (2014) (0)
Hautkrebsforschung reloaded: Paradigmenwechsel in der Dermatoonkologie (2013) (0)
[Tumor-specific therapy strategies in oncology]. (2001) (0)
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry (2022) (0)
S3-Guideline Diagnosis, Treatment and Care of Melanomas: Methodological Foundations (2010) (0)
606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology (2022) (0)
Preoperative serum lactate dehydrogenase, but not BRAF or NRAS mutational status are prognostic factors after pulmonary melanoma metastasectomy (2022) (0)
A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma (2016) (0)
Neurofeedback Treatment Affects Affective Symptoms, But Not Perceived Cognitive Impairment in Cancer Patients: Results of an Explorative Randomized Controlled Trial (2023) (0)
Clinical Perspectives TM Highlights from the Perspectives in Melanoma XII Conference (2009) (0)
Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival (2011) (0)
PO-263 Epigenetic modulation of cell metabolism and its effects on cell survival in melanoma (2018) (0)
14. Alkylating Agents (2013) (0)
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD‐1 inhibitors (2021) (0)
Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients (2011) (0)
Mykotische und bakterielle Infektionen (2010) (0)
8th Annual Meeting of the German Working Group for Gene Therapy (DAG-GT e.V.) (2014) (0)
Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study (2022) (0)
Avelumab Induced Severe Disabling Myositis in A Patient with Merkel Cell Carcinoma (2020) (0)
308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma (2020) (0)
Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma (2014) (0)
Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. (2020) (0)
The "Intimarzt" (intimate doctor) Model Project: Anonymous Remote Diagnosis of Sexually Transmitted Diseases. (2023) (0)
Model soups improve performance of dermoscopic skin cancer classifiers. (2022) (0)
Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure (2017) (0)
Prospective center-randomized trial of melanoma surveillance in 3,833 patients: An analysis of the early detection of recurrences (2007) (0)
Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB). (2019) (0)
Abstract 5056: A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs (2012) (0)
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) (2022) (0)
30 years German Dermatologic Cooperative Oncology Group (DeCOG) (2021) (0)
Contents Vol. 26, 2003 (2003) (0)
[Working Group on Dermatological Oncology -- a dermatological success story]. (2014) (0)
Comprar Handbook Of Cutaneous Melanoma. A Guide To Diagnosis And Treatment | Dirk Schadendorf | 9781908517975 | Springer (2013) (0)
Immune escape mechanisms in melanoma patients vaccinated with peptide pulsed dendritic cells (1998) (0)
The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment. (2014) (0)
Chapter 17 Immunotherapy of Melanoma: A New Era (2011) (0)
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours (2020) (0)
Vorwort (2016) (0)
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial, (2023) (0)
PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma (2020) (0)
3351 Concordance of BRAF V600E mutation status in metastatic melanoma patients by comparison of results from circulating tumor DNA and tissue-based testing (2015) (0)
Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS (2022) (0)
Ein neues 10mer Epitop aus dem TRP2 (Tyrosinase related protein 2) Differenzierungsantigen des Melanoms aktiviert CD8+ T-Lymphocyten aus HLA-A1+, HLA-A2- und HLA-A1-, HLA-A2+ Donoren (2003) (0)
Qualitative Einschätzung von Informationsbroschüren für Melanom-Patiente (2017) (0)
C URRENT OPINION New developments in biomarkers for melanoma (2013) (0)
Facial Variant of Eruptive Vellus Hair Cysts: A Case Report and Brief Review of the Literature (2010) (0)
Pegylated Interferons in the Adjuvant Treatment of Melanoma (2009) (0)
[Cutaneous angiosarcoma clinically presenting as Quincke's edema]. (2021) (0)
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter DeCOG study on 637 patients from the prospective skin cancer registry ADOREG (2023) (0)
Treatment of Primary Tumor and Locoregional Disease (2013) (0)
New markers for the diagnosis and therapy of tumors (2000) (0)
CEACAM1: a novel target of MITF in malignant melanoma (2016) (0)
Association of critical losses in X chromosome with melanoma progression: An EORTC Melanoma group study. (2008) (0)
Abstract 5254: Sentinel lymph node detection and in vivo/ex vivo assessment of melanin distribution by means of multispectral optoacoustic tomography (MSOT) in patients with malignant melanoma (2015) (0)
Randomized P hase I II S tudy o f T emozolomide V ersus Dacarbazine i n t he T reatment o f P atients W ith A dvanced Metastatic M alignant M elanoma (2000) (0)
3D data related to: Identification and quantification of hidden melanoma metastases in human sentinel lymph nodes using light sheet fluorescence microscopy (2020) (0)
Fluoreszenz‐Markierung mittels Indocyanin‐Grün bei der Sentinel‐Lymphknoten‐Exstirpation in der Dermatoonkologie (2012) (0)
Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al. (2015) (0)
C URRENT OPINION Brain metastasis: opportunity for drug development? (2012) (0)
1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
[Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma]. (2011) (0)
Fortschritte bei Systemtherapie verbessern Prognose (2021) (0)
Primäres amelanotisches Harnblasenmelanom -eine seltene Ursache für eine Hämaturie (2000) (0)
Gegen den Hautkrebs: Forschung zur Überwindung immuntherapeutischer Hürden beim malignen Melanom (2012) (0)
Oberrheinische Arbeitsgemeinschaft für Onkologie (OAO/GTOR/AOR) / Deutsche Krebsgesellschaft e.V. (2003) (0)
Innovative Konzepte zur Immunintervention bei Hauttumoren: Vakzinierung mit Tumorantigen beladenen dendritischen Zellen (2000) (0)
A randomised phase 2 study of Paclitaxel with or without Trametinib or Pazopanib in advanced wild type BRAF melanoma (2017) (0)
Phase II-Studie zur Vakzinierung von Melanompatienten mit Tyrosinase-Peptiden und GM-CSF (2000) (0)
Die neue S3-Leitlinie „Melanom“ (2013) (0)
Isolierte zerebrale Suszeptibilitätsartefakte bei Patienten mit malignem Melanom: Metastase oder nicht? (2012) (0)
Immer eine morphologische Beschreibung beifügen (2018) (0)
1. Wertheimer Onkologie-Gespräch «Das nicht-kleinzellige Bronchialkarzinom (NSCLC) mit Taxotere® frühzeitig wirksam behandeln» (2003) (0)
Vorteile einer präoperativen SPECT/CT in der Detektion von Sentinel-Lymphknoten beim malignen Melanom Eine retrospektive Analyse von 406 Patienten (2011) (0)
Laudatio anlässlich der Emeritierung von Prof. Dr. Claus Garbe (Tübingen) (2019) (0)
Vakzination mit dendritischen Zellen im Vergleich zu DTIC – Ergebnisse einer Phase-III-Studie (2004) (0)
Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten (2013) (0)
Interleukine und Wachstumsregulation von Melanomzellen (2004) (0)
Das Serumproteomprofil als prognostischer Index beim malignen Melanom (2004) (0)
Mikro- und Makrodeletionen chromosomaler Sequenzen führen zum Verlust der HLA Klasse I Expression auf Tumorzellen (2004) (0)
Intraoperative use of LIGHTVISION: a novel fluorescence navigation system using indocyanine green for sentinel lymph node biopsy in skin cancer patients (2018) (0)
Aftercare and Follow-up in malignant Melanoma (2013) (0)
Prognostische Genexpressionstests beim Melanom auf dem Weg in die Routine (2020) (0)
Kardiovaskuläre Risikofaktoren bei Psoriasis - Ergebnisse aus der Heinz Nixdorf Recall Studie (2011) (0)
Neue Tumor-Antigene im Zusammenhang mit Melanom-assoziierter Retinopathie (2004) (0)
Prospektive vergleichende Untersuchung zweier Nachsorgeschemata bei 2354 Patienten mit malignem Melanom (2011) (0)
Seltene Tumoren des Integuments (1999) (0)
Therapie des malignen Melanoms (2015) (0)
Pyruvat-Kinase Typ M2: Ein neuer prognostischer Marker beim malignen Melanom (2003) (0)
Immunonkologie im Fokus (2014) (0)
Hautkrebs: 3. Interdisziplinres Expertenforum, Hamburg, Dezember 2012 (2013) (0)
Bräunungscremes und Bräunungsbeschleuniger - Übersicht, Risiken, praktische Tipps (2005) (0)
Langerhans-Zell-Histiozytose mit Hautveränderungen im Erwachsenenalter (2000) (0)
Translationale ADO-Registerstudie TRIM-ADJUVANT beim Melanom (2020) (0)
Zertifizierte Fortbildung (2007) (0)
Malignes Melanom: Optionen für Patienten im fortgeschrittenen Stadium (2018) (0)
Vakzinationstherapie beim Melanom (2000) (0)
Klinische Pharmakologie (2011) (0)
Analyse der humoralen Immunantwort gegen Tumorantigene mittels Serum-Antikörper Detektions Arrays (2004) (0)
Melanome der Atemwege und des Gastrointestinaltrakts (2006) (0)
Freie Vorträge (2015) (0)
Limitierte Wirkung von Anti-PD-1 bei fortgeschrittenen Hauttumoren von Patienten mit hämatoonkologischer Grunderkrankung: eine retrospektive multizentrische Studie der ADO (2019) (0)
Title Pages / 1. Interdisziplinäres Expertenforum Hautkrebs / Table of Contents / Teilnehmerverzeichnis (2011) (0)
Sachwortverzeichnis Band 26, 2003 (2003) (0)
Band 25, Heft 1, Februar 2002 (2002) (0)
Das anorektale maligne Melanom (2008) (0)
Früherkennung von Hauttumoren (2003) (0)
Interleukin-2 und Checkpoint-Inhibition als erfolgreiche Therapiesequenz beim metastasierten Melanom: Fallbericht und retrospektive Analyse an 52 Patienten (2017) (0)
Quantensprung durch zielgerichtete und Immuntherapie beim Melanom (2021) (0)
«Optimierung der palliativen Therapie gastrointestinaler Tumoren» (2003) (0)
Komplette Remission kutaner Satelliten- und in-transit Metastasen eines malignen Melanoms nach isolierter hyperthermer Extremitätenperfusion und topischer Imiquimodbehandlung (2003) (0)
Lichen aureus : eine seltene Form der Pigmentpurpura (1993) (0)
Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie (2022) (0)
O2-Aufnahmekapazitätmessung chronischer Ulcera nach topischer Hämoglobinapplikation mittels photooptoakustischer Tomografie -Initiale Ergebnisse einer prospektiven Studie- (2015) (0)
First-line-Therapie beim inoperablen oder metastasierten Melanom (2020) (0)
Hautkrebs: 1. Interdisziplinres Expertenforum, Hamburg, Dezember 2010 (2011) (0)
Onkokardiologie: Neue Herausforderungen, neue Möglichkeiten./ Oncocardiology: new challenges, new opportunities. (2020) (0)
Immuntherapien bei soliden Tumoren: Auf dem Weg zum Standard beim Melanom (2015) (0)
30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO) (2021) (0)
Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim Melanom (2017) (0)
«Sicherheit für die Zukunft – Pathogeninaktivierung von Thrombozytenkonzentraten», Symposium im Rahmen des 36. Jahreskongresses der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie e.V., Innsbruck, 18. September 2003 (2003) (0)
Manifestation einer systemischen Sklerodermie unter Therapie mit pegyliertem Interferon alpha bei metastasiertem Melanom (2004) (0)
Kosten und Nutzen der Ausbreitungsdiagnostik beim Melanom (2006) (0)
Primäre extrakutane maligne Melanome: Ein Überblick unter besonderer Berücksichtigung der Therapie (1998) (0)
Moderne Pharmakotherapie des malignen Melanoms (2011) (0)
Tödliche Schwellung der Leiste – Klarzellsarkom: eine seltene, aber wichtige Differenzialdiagnose zum malignen Melanom (2020) (0)
[Working group of the Dermatologic Oncology]. (2009) (0)
Title Pages / 2. Interdisziplinäres Expertenforum Hautkrebs / Table of Contents / Teilnehmerverzeichnis (2012) (0)
Title Page / Impressum / Inhalt (2015) (0)
Behandlungsalgorithmus bei Patienten mit malignem Melanom (2014) (0)
Immunonkologie «Coming of Age» - die nächste Generation der Immun-Checkpoint-Inhibitoren (2014) (0)
Characterisation and outcome of RAC1 mutated melanoma. (2023) (0)
Emerging Therapies and Combination Approaches (2013) (0)
Diagnostik und Therapie von gastrointestinalen Stromatumoren (GIST) (2015) (0)
Somatische Gentherapie beim malignen Melanom (1997) (0)
Tumortherapie - eine interdisziplinre Aufgabe: Herbstsymposium des Onkologischen Arbeitskreises Mannheim / Abschiedssymposium fr Prof. Dr. Wolfgang Queisser, Mannheim, September 2001 (2001) (0)
Special · Krebskongress 2004: Termine (2003) (0)
Seltene melanozytäre Tumoren (2006) (0)
Palliative Therapie des malignen Melanoms im Stadium IV (2009) (0)
Therapie mit Epoetin beta: Sicher und effektiv in der Prävention und Behandlung der tumorinduzierten Anämie (2003) (0)
Neue Arzneimittel lassen hoffen (2018) (0)
Mastozytosen ± Diagnostik, Klassifikation, Therapie, aktuelle pathophysiologische Ansätze (2005) (0)
Inhalt Band 26, 2003 (2003) (0)
Behandlung von Melanomen der Schleimhäute und Meningen (2006) (0)
Abstract 2487: Distinct venous brain vessels provide structures for T lymphocyte recruitment to brain tumors in mouse models of intracranial melanoma (2022) (0)
Das Wichtigste für die Praxis (2013) (0)
Hautkrebs: 2. Interdisziplinres Expertenforum, Hamburg, Dezember 2011 (2012) (0)
Einsatzmöglichkeiten in der klinischen Routinediagnostik (2016) (0)
Experimentelle Therapie des Melanoms (2001) (0)
Vakzinierungstrategien mit Hilfe der Gentherapie (2006) (0)
CME Zertifizierte Fortbildung (2016) (0)
Arbeitsgemeinschaft Dermatologische Onkologie – eine dermatologische Erfolgsgeschichte (2014) (0)
Blockade von Immuncheckpoints (2016) (0)
Aktuelle Therapiestudien beim Merkel-Zell-Karzinom (2020) (0)
Qualitätsmanagement und Zertifizierung in der Onkologie. Bericht vom DGHO-Symposium anlässlich der DGHO-Jahrestagung am 30.09.2001 in Mannheim (2002) (0)
Response to comment - Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphology. (2021) (0)
Maligne Hauttumoren: Immunologische Checkpoint-Kontrolle (2013) (0)
Abstract 571: Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma (2017) (0)
836P Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe (2022) (0)
Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2017) (0)
Liebe Leserinnen und Leser (2016) (0)
[Interleukin 7 in dermatology. Molecular, immunologic and preclinical aspects]. (1995) (0)
Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial. (2015) (0)
An animal model of cutaneous cyst development enables the identification of three QTLs including the homologue of a human locus (TRICY1). (2019) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Contents Vol. 87, 1999 (2000) (0)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
1122P Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020) (0)
Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (0)
HIV‐infection during treatment of a chronic hepatitis B virus infection: implications for PrEP? (2012) (0)
XXXII. Annual Meeting of the ADF (2005) (0)
102 INVITED Current clinical experience with melanoma vaccines: peptides, proteins and dendritic cells (2007) (0)
Deep Learning Assisted Diagnosis of Onychomycosis on Whole-Slide Images (2022) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
[Obituary for Prof. Dr. med. Christiane Voit (Berlin)]. (2015) (0)
Eine nicht-interventionelle, multi-zentrische, prospektive Studie zur kombinierten Behandlung von fortgeschrittenem Melanom mit Dabrafenib und Trametinib im praktischen All-tag ("real-world setting"): COMBI-r (2017) (0)
AnalysisofDermatologic Events inVemurafenib-TreatedPatients WithMelanoma (2013) (0)
Immunological Strategies to Fight Skin Cancer (2004) (0)
1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO (2021) (0)
Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma (2021) (0)
[Forward: anti-tumor immunity and tumor immunology]. (2014) (0)
Effects of various synthetic retinoids on proliferation and melanogenesis towards human melanoma cells in vitro (1993) (0)
Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. (2021) (0)
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials (2016) (0)
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma (2023) (0)
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. (2022) (0)
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (0)
Drug resistance in melanoma—anything new? (2001) (0)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (0)
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2022) (0)
cTAGE are potential multiple myeloma associated antigens [In: Cancer immunotherapy 2006 meets strategies for immunetherapy p.414] (2007) (0)
Optimale Systemtherapie beim kutanen Melanom (2017) (0)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (0)
Novel Predictive Biomarkers in Melanoma Treatment with Ipilimumab (2015) (0)
LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma (2022) (0)
Corrigendum to 'Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data' [Eur J Cancer, 119 (September 2019) Pages 30-34]. (2019) (0)
1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma (2021) (0)
P683Cardiovascular adverse events associated with BRAF and MEK inhibitors (2019) (0)
Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53 Merkel cell carcinoma (MCC) (2022) (0)
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (0)
ctDNA as a noninvasive monitoring tool in metastatic melanoma. (2019) (0)
Ex vivo cytokine gene transfer in melanomas by using particle bombardment. (2000) (0)
Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies (2018) (0)
Staging bei Patienten mit fortgeschrittenem Stadium eines malignen Melanoms: Wertigkeit der Ganzkörper-MRT im diagnostischen Vorgehen (2006) (0)
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways (2018) (0)
Vorwort (2014) (0)
572 Photoaging smartphone apps for skin cancer prevention in German adolescents: The Sunface randomized trial (2017) (0)
XPG D1104 single-nucleotide polymorphisms and the prognosis of melanoma. (2009) (0)
Editorial Board / Imprint / Innentitel / Inhalt (2016) (0)
1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS (2020) (0)
Vektoren zur gentherapeutischen tumorbehandlung (1999) (0)
Dermatopathology SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma (2004) (0)
Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo (2019) (0)
The vascular phenotype, vessel stabilization and maturation affect the resistance to anti-angiogenic therapy in malignant melanoma (2010) (0)
Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib (2021) (0)
A five‐year observance of changes in the cardiovascular risk profile in 505 HIV‐positive individuals (2012) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Abstract 5647: Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy (2017) (0)
Gene-based Vaccination Against Malignant Melanoma (2003) (0)
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study (2016) (0)
Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma. (2023) (0)
Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI) (2019) (0)
TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities (2023) (0)
Merkel Cell Carcinoma Register of the ADO - the first Evaluation (2013) (0)
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2023) (0)
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI). (2019) (0)
Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2018) (0)
Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways (2019) (0)
The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment—Differences between the patient's and the physician's perspective. (2015) (0)
Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease qq (2014) (0)
Volume Index 2011 (2011) (0)
Inside the USCAP Journals (2022) (0)
[Comment on the contribution by J. Petres et al. Effective lymph node dissection in primary malignant melanoma]. (1996) (0)
The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression (2016) (0)
Is there a role for immune checkpoint blockade in metastatic uveal melanoma? (2015) (0)
Relevance of autoantibody profiles in the early detection of cancer (2008) (0)
Dose Seeking Evaluation of a Novel Heterologous Primeboost Immunotherapy in Stage III and IV Metastatic Melanoma Patients (2004) (0)
Interaktives Expertenforum Melanom: Juni 2016 (2016) (0)
7 Evolution of cross-resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma (2018) (0)
Cutaneous melanoma (0)
Myeloprotection of amifostine in patients with stage IV malignant melanoma treated with fotemustine chemotherapy: 411 (1997) (0)
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions (2022) (0)
Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapy (2016) (0)
COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study (2023) (0)
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (2021) (0)
Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors (2021) (0)
Apoptosis in Melanoma (2006) (0)
Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials (2016) (0)
Abstract 3031: PHIP is a therapeutic target for triple negative solid tumors (2017) (0)
Metastasiertes pigmentiertes epitheloides Melanozytom bei einer 7‐jährigen Patientin (2021) (0)
Temozolomide (TMZ) in combination with pegylated interferon alfa-2b for stage IV metastatic melanoma: A multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2016) (0)
European Journal of Skin Cancer Editorial (2023) (0)
Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist (2021) (0)
Bacteria as Vectors for Gene Therapy of Cancer (2003) (0)
814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3 (2022) (0)
New TRP-2-derived T helper epitopes identified in HLA-DRB1*0301 transgenic mice elicit spontaneous T cell responses in HLA-DRB1*03 and HLA-DRB1*04 melanoma patients (2004) (0)
Deep learning detection of melanoma metastases in lymph nodes (2023) (0)
Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma (2022) (0)
Skin Cancer Classification Using Convolutional Neural Networks with Integrated Patient Data: A Systematic Review (Preprint) (2020) (0)
PD-L1 EXPRESSION AND EFFICACY IN PATIENTS TREATED WITH PEMBROLIZUMAB VS IPILIMUMAB FOR ADVANCED MELANOMA IN KEYNOTE-006 (2016) (0)
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. (2023) (0)
Guideline-Based Context-Sensitive Decision Modeling for Melanoma Patients (2022) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem (2019) (0)
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i (2020) (0)
Vorwort (2011) (0)
Review Genetic Alterations and Personalized Medicine in Melanoma (2014) (0)
Management of partial and non‐responding cutaneous squamous cell carcinoma (2021) (0)
NF1 mutations in conjunctival melanoma (2018) (0)
Regulatory T Cells in + Foxp 3 + CD 25 Transgenic Mice Despite the Depletion of ret Skin Melanoma Development in Mahnke (2009) (0)
Efficacy of PD-1 based Immunotherapy after radiological Progress under targeted Therapy in Melanoma (2019) (0)
Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma (2023) (0)
1077P Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE) (2021) (0)
L5 RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodies (2020) (0)
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (0)
Molecular features of response to anti-PD-1 therapy. (2016) (0)
dictors of Sun Protection Behaviors and Severe Sunburn B & P n International Online Study (2010) (0)
Statin use and its effect on all-cause mortality of melanoma patients (2017) (0)
The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma (2014) (0)
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence (2023) (0)
Vorwort (2015) (0)

This paper list is powered by the following services:

Other Resources About Dirk Schadendorf

www.uni-due.de

What Schools Are Affiliated With Dirk Schadendorf?

Dirk Schadendorf is affiliated with the following schools:

Johns Hopkins University
University of Tübingen
University of Texas Southwestern Medical Center
University of Duisburg-Essen
Saarland University
Medical University of Graz
Humboldt University of Berlin
MD Anderson Cancer Center
University of Sydney
University of Oxford
University of Cologne
Kiel University
Aix-Marseille University
University of Glasgow
University of Western Australia
Yale University
University of Wales

Dirk Schadendorf's Academic­Influence.com Rankings

Dirk Schadendorf's Degrees

Why Is Dirk Schadendorf Influential?

Dirk Schadendorf's Published Works

Published Works

Other Resources About Dirk Schadendorf

What Schools Are Affiliated With Dirk Schadendorf?

Dirk Schadendorf's AcademicInfluence.com Rankings